Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
Authors:
Top Cited Papers
Open Access
- 1 February 2024
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 90 (6) , 1190-1199
Abstract
No abstract availableKeywords
Funding Information
- Regeneron Pharmaceuticals Inc
This publication has 28 references indexed in Scilit:
- Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 WeeksDermatology and Therapy, 2021
- Interpretability of the Quality Of Life in Hand Eczema QuestionnaireJournal of Investigative Dermatology, 2020
- Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic DermatitisJAMA Dermatology, 2020
- Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Hand Eczema in AdultsThe Patient - Patient-Centered Outcomes Research, 2019
- Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)Journal of Dermatological Science, 2019
- Dupilumab for hand eczemaJournal of the American Academy of Dermatology, 2018
- Cross-Cultural Validation of the Quality of Life in Hand Eczema Questionnaire (QOLHEQ)Journal of Investigative Dermatology, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2016
- Atopic dermatitis results in intrinsic barrier and immune abnormalities: Implications for contact dermatitisJournal of Allergy and Clinical Immunology, 2013
- Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costsJournal of the American Academy of Dermatology, 2006